Mark J Field

Senior executive with over 30 years’ experience spanning both preclinical research & clinical development working at MSD, Parke-Davis, Pfizer, UCB & Grunenthal. At Grunenthal I was Head of R&D Pain innovation - where I have developed a patient-inspired R&D model with responsibility for; people (~200) budget (~€150M) to drive projects from research to clinical Phase III. Broad experience developing new pain medicines and have been associated with over 30 compounds progressing into clinical development. I led the research at Parke-Davis and Pfizer that identified Gabapentin (Neurontin®) and Pregabalin (Lyrica®) as analgesics and identified their MoA. Lyrica now treats patients with pain disorders, epilepsy and anxiety - generating 2017 revenues of over $5 Billion.